HAEMONETICS CORP
For the period ended Mar 28, 2026. Filed Jun 9, 2026.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Mar 28, 2026 · Filed Jun 9, 2026
Contents
Cover page
Show cover page
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a)
of the Securities Exchange Act of 1934
| Filed by the Registrant x | Filed by a Party other than the Registrant ☐ |
|---|
| Check the appropriate box: | |
|---|---|
| ☐ | Preliminary Proxy Statement |
| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| x | Definitive Proxy Statement |
| ☐ | Definitive Additional Materials |
| ☐ | Soliciting Material under §240.14a-12 |
(Name of Registrant as Specified in Its Charter)
| Payment of Filing Fee (Check the appropriate box): | |
|---|---|
| x | No fee required. |
| ☐ | Fee paid previously with preliminary materials. |
| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. |
OUR PURPOSEwe make it possibleyou make it matterWe challenge ourselves every day to drive greater possibilities and meaningfully advance healthcare.
Haemonetics provides a suite of innovative medical technology solutions that improve the quality, effectiveness and efficiency of care. We challenge ourselves to think big and make new possibilities a reality, so that our customers can make it matter for patients, every single day.WHAT WE DOFor commercial plasma, we offer innovative technologies that enable higher plasma yield collections, help improve productivity and quality in our customers’ centers and enhance the overall donor experience.For hospitals, we provide quality solutions designed to enhance clinical outcomes, improve procedural effectiveness and advance healthcare standards.For blood centers, we advance products and services to help ensure blood safety, improve operational efficiency and collect the blood components in the greatest demand.
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS
Friday, July 24, 2026
8:00 A.M. Eastern Time
125 Summer Street, Boston, Massachusetts 02110
To Our Shareholders:
The 2026 Annual Meeting of Shareholders of Haemonetics Corporation, a Massachusetts corporation (the "Company"), will be held on Friday, July 24, 2026 at 8:00 A.M., Eastern Time, at the offices of the Company, 125 Summer Street, Boston, Massachusetts 02110, for the following purposes:
| 1 | To elect the eight director nominees named in the proxy statement to one-year terms expiring in 2027; |
| 2 | To approve, on an advisory basis, the compensation of our named executive officers; |
| 3 | To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending April 3, 2027; |
| 4 | To approve an amendment and restatement of the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan; |
| 5 | To approve an amendment and restatement of the Haemonetics Corporation Amended and Restated 2007 Employee Stock Purchase Plan; and |
| 6 | To transact such other business as may properly come before the meeting. |
The foregoing items of business are more fully described in the proxy statement accompanying this Notice of Annual Meeting of Shareholders.
We are pleased to continue utilizing the Securities and Exchange Commission rules that allow companies to furnish proxy materials to their shareholders on the Internet. We believe these rules allow us to provide you with the information you need while lowering the costs of delivery and reducing the environmental impact of the meeting. On or about June 10, 2026, we will mail to our shareholders of record as of May 22, 2026, the record date for the meeting, a Shareholder Meeting Notice and Important Notice Regarding the Availability of Proxy Materials containing instructions on how to access our proxy statement and our 2026 Annual Report to Shareholders (unless the shareholder previously requested electronic or paper delivery on an ongoing basis).
Your vote is important. Whether or not you plan to attend the meeting, we encourage you to vote your shares. Accordingly, we request that as soon as possible you vote via the Internet or, if you have received printed proxy materials, you vote via the Internet, by telephone or by mailing your completed proxy card or voter instruction form.
By Order of the Board of Directors,
Michelle L. Basil
Corporate Secretary
Boston, Massachusetts
June 10, 2026
IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 24, 2026: This proxy statement and the Company’s 2026 Annual Report to Shareholders are available at www.envisionreports.com/HAE.
HAEMONETICS CORPORATION | 2026 Proxy Statement 1
TABLE OF CONTENTS
| Notice of Annual Meeting of Shareholders | 1 |
|---|---|
| Proxy Statement Summary | 3 |
| Item 1—Election of Directors | 9 |
| Haemonetics Board of Directors | 9 |
| Board’s Role and Responsibilities | 13 |
| Board Leadership Structure | 14 |
| Board Policies and Processes | 16 |
| Directors’ Compensation | 17 |
| Item 2—Advisory Vote on Executive Compensation | 19 |
| Executive Officers | 20 |
| Compensation Discussion and Analysis | 22 |
| Compensation Committee Report | 37 |
| Executive Compensation Tables | 38 |
| CEO Pay Ratio | 45 |
| Pay Versus Performance | 46 |
| Timing of Equity Awards | 50 |
| Securities Trading Policy | 51 |
| Hedging Policy | 51 |
| Item 3—Ratification of Independent Registered Public Accounting Firm | 52 |
| Audit Fees and Services | 53 |
| Audit Committee Report | 53 |
| Item 4—Approval of Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan | 55 |
| Overview and Background | 55 |
| Alignment with Best Practices | 57 |
| Summary of the Amended Plan | 57 |
| New Plan Benefits | 62 |
| Item 5—Approval of Haemonetics Corporation Amended and Restated 2007 Employee Stock Purchase Plan | 63 |
| Summary of the Plan | 63 |
| United States Federal Tax Consequences | 65 |
| New Plan Benefits | 65 |
| Share Ownership Information | 66 |
| Equity Compensation Plans | 66 |
| Security Ownership of Certain Beneficial Owners, Directors and Management | 67 |
| Delinquent Section 16(a) Reports | 68 |
| General Information About the Meeting and Voting | 69 |
| Additional Information | 72 |
| Solicitation of Proxies | 72 |
| Shareholder Proposals for Next Year’s Annual Meeting | 72 |
| Other Matters | 72 |
| Incorporation by Reference | 72 |
| Delivery of Documents to Shareholders Sharing an Address | 73 |
| Appendix A—Non-GAAP Financial Reconciliations | 74 |
| Appendix B—Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan | 77 |
| Appendix C—Haemonetics Corporation Amended and Restated 2007 Employee Stock Purchase Plan | 90 |
2 HAEMONETICS CORPORATION | 2026 Proxy Statement
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.